| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8cdfbc70d9776e1ea4502b21128b30c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2006-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e12da47c9e1f9218b9f30757d6e1c8a1 |
| publicationDate |
2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0617378-B1 |
| titleOfInvention |
USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO A TRANSPLANTED ISLET AFTER ISLET TRANSPLANTATION; AND IMPROVING THE VIABILITY OF AN ISLET IN AN ISLET TRANSPLANTATION |
| abstract |
AGENT FOR DAMAGE SUPPRESSION TO AN ISLET TRANSPLANTED AFTER ISLET TRANSPLANTATION AND USES OF AN IL-6 INHIBITOR. The present inventors investigated anti-IL-6 receptor antibodies for their effect in suppressing damage to transplanted islets after islet transplantation. As a result they demonstrate that anti-IL-6 receptor antibodies reduced damage to transplanted islets, improved islet survival and corrected hyperglycemia in recipients. Furthermore, they revealed that administration of the anti-IL-6 receptor antibodies of the present invention suppressed the production of inflammatory cytokines by infiltrating cells after transplantation. Specifically, the present inventors have disclosed for the first time that damage to transplanted islets after islet transplantation can be suppressed by using anti-IL-6 receptor antibodies in accordance with the present invention. |
| priorityDate |
2005-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |